Fox Chase Cancer Center creates department of bone marrow transplant, cellular therapies
Click Here to Manage Email Alerts
Fox Chase Cancer Center has established a new department of bone marrow transplant and cellular therapies.
Henry Chi Hang Fung, MD, FACP, FRCPE, director of the Fox Chase-Temple University Bone Marrow Transplant Program and vice chair of the department of hematology/oncology, will chair the new department.
“This is very positive because the institution has recognized that this is one of the best clinical programs in the health system, and it has very big potential to continue to grow,” Fung said in a press release. “Last year we were ranked as an institution with one of the best survival outcomes in the country.”
The board-certified hematologic oncologists in the bone marrow transplant program perform more than 100 blood and bone marrow transplants annually.
“We’re very pleased by the continuation and expansion of the bone marrow transplant and cellular therapies,” Martin J. Edelman, MD, chair of the department of hematology/oncology at Fox Chase, said in the release. “It’s exciting both as part of standard of care, as well as in terms of investigations to further advance the treatment of patients with malignancy.
“We will continue to do a lot of collaborative work in expanding the use of cellular therapies,” Edelman added. “I think it just recognizes the growing importance and distinctiveness of cellular therapy and bone marrow transplants from the types of drug therapies that are done in the rest of medical oncology.”
Click Here to Manage Email Alerts